bromocriptine has been researched along with docetaxel anhydrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, Y; Du, Y; Fu, H; Kavuri, S; Kucuk, O; Li, X; Mamouni, K; Wu, D; Yang, Y | 1 |
1 review(s) available for bromocriptine and docetaxel anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for bromocriptine and docetaxel anhydrous
| Article | Year |
|---|---|
Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bromocriptine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Docetaxel; Dopamine Agonists; Drug Repositioning; Drug Synergism; Humans; Male; Mice, Nude; Prostatic Neoplasms; Receptors, Dopamine D2; Xenograft Model Antitumor Assays | 2018 |